<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01992029</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2012/13</org_study_id>
    <nct_id>NCT01992029</nct_id>
  </id_info>
  <brief_title>Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>MIRSLA</acronym>
  <official_title>Etude de l'Expression Des Micro-RNA Comme Biomarqueur Diagnostic et Pronostic Dans la Sclérose Latérale Amyotrophique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal goal is to demonstrate that a specific pattern of microRNA (miRNA) expression
      can be correlated with the definite diagnostic of Amyotrophic Lateral Sclerosis (ALS). The
      investigators will use biological sample (from muscle biopsy, Cerebrospinal Fluid (CSF) and
      blood sample) collected in three control populations: definite ALS patients according to El
      Escorial diagnostic criterion, control patients without any neurological disease having an
      orthopedic surgery for shoulder disease, and control patient explored for peripheral
      neuropathy and myopathy. A second goal will correlate the miRNA pattern to the severity
      and/or progression rate of the motor neurons define as the progression rate of the
      Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) score/year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic Lateral Sclerosis is an adult-onset neuro degenerative disease leading to muscle
      wasting, palsy and death due to respiratory failure within 3 to 5 years. The only effective
      drug (Riluzole) increases the life expectancy for about three months, knowing that on
      average, the diagnostic is given after a delay of one year in France. The identification of
      new biomarkers for early diagnostic is therefore of fundamental importance. This could
      improve the treatment efficacy but also give important clues about the prognostic, the rate
      of evolution and overall help identify new targets for future therapeutics. The
      investigators' goals are to find specific miRNA patterns expression associated to ALS in
      humans and use those patterns as diagnostic and prognostic tools.

      miRNA are non-coding small fragments of RNA that binds mRNA and can down regulate their
      expression. In humans, around 700 miRNA have been so far identified. The role of miRNA in
      human pathology is well established in various types of cancer, but recent works have
      emphasize their role in neuro degenerative diseases and their expression profile can
      considered specific for Alzheimer, Parkinson and Huntington diseases. Very few data are
      currently available about their expression pattern in ALS. Previous studies have however
      shown that down regulating of some miRNA in spinal cord Moto neurons can trigger an ALS-like
      clinical phenotype. A more recent work on transgenic murine model SOD1 G93A has demonstrated
      the role of the specific miRNA206 in regulating the re-innervation processes at the
      neuro-muscular junction. Mi206 have the ability to promote the re-innervation process and
      therefore to slow the disease progression.

      This research aimed to study the expression of more than 700 miRNA in four different groups
      (20 patients per group): ALS patients, normal control having a shoulder surgery during which
      they will have a muscle (deltoid) biopsy, patients explored for peripheral neuropathy with a
      blood sample, a lumbar puncture for CSF examination and neuro-muscular biopsy and patient
      explored for myopathy with a blood sample, a lumbar puncture for CSF examination and a
      muscular biopsy. The ALS group will be followed up every 4 months with ALSFRS scoring and
      blood sample and a second CSF sample only at M12. miRNA pattern expression will be compared
      and considered significant for a 2-fold change.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>miRNA expression</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>miRNA expression pattern in ALS patients compared to control patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>miRNA evolution</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>Evolution of miRNA expression level in blood and CSF of ALS patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miRNA expression pattern in different ALS patients compared to control patients predictive of the clinical phenotype and of the progression of the disease.</measure>
    <time_frame>Day 0 (inclusion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in diffusivity parameters of MRI</measure>
    <time_frame>At inclusion (Day 0) and 8 month after inclusion</time_frame>
    <description>Difference in diffusivity parameters of MRI between ALS subjects and control groups</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>ALS</condition>
  <arm_group>
    <arm_group_label>ALS Patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients suffering from neuropathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients suffering from myopathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control subjects</arm_group_label>
    <description>control patients without any neurological disease having an orthopedic surgery for shoulder disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical evaluation</intervention_name>
    <description>Clinical evaluation using MRC scale, Norris bulbar scale, ALSFRS score and respiratory evaluation ( Vital Capacity, PiMax and SNIP) at M0, M4, M8, M12</description>
    <arm_group_label>ALS Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Muscular biopsy</intervention_name>
    <description>Muscular biopsy at M0</description>
    <arm_group_label>ALS Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumbar puncture</intervention_name>
    <description>Lumbar puncture at M0 and M12</description>
    <arm_group_label>ALS Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling at M0, M4, M4, M8 and M12</description>
    <arm_group_label>ALS Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurological assessments</intervention_name>
    <description>Neurological assessments (MRC score and cognitive scales: MMS and BREF)</description>
    <arm_group_label>Control patients suffering from neuropathy</arm_group_label>
    <arm_group_label>Control patients suffering from myopathy</arm_group_label>
    <arm_group_label>Control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neuro-muscular biopsy and lumbar puncture</intervention_name>
    <description>Neuro-muscular biopsy and lumbar puncture for patients explored for peripheral neuropathy</description>
    <arm_group_label>Control patients suffering from neuropathy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Muscular biopsy</intervention_name>
    <description>Muscular biopsy for patient explored for myopathy</description>
    <arm_group_label>Control patients suffering from myopathy</arm_group_label>
    <arm_group_label>Control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood sample for qRT PCR, detection and quantification for miRNA</description>
    <arm_group_label>Control patients suffering from neuropathy</arm_group_label>
    <arm_group_label>Control patients suffering from myopathy</arm_group_label>
    <arm_group_label>Control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cervical spinal cord and brain MRI</intervention_name>
    <description>ALS patients : MRI at inclusion and Month 8 Control patients suffering from neuropathy : MRI at inclusion and Month 8 Control patients suffering from myopathy : MRI at inclusion Control subjects : MRI at inclusion</description>
    <arm_group_label>ALS Patients</arm_group_label>
    <arm_group_label>Control patients suffering from neuropathy</arm_group_label>
    <arm_group_label>Control patients suffering from myopathy</arm_group_label>
    <arm_group_label>Control subjects</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood Cerebrospinal fluid muscle
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from ALS, neuropathy, myopathy or control subjects having a shoulder
        surgery during which they will have a muscle (deltoid) biopsy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For ALS patients:

          -  Age between 45 and 70 years old

          -  Patients with definite criteria of ALS according to revised El Escorial criterion
             (1998).

          -  ALS Patients with a clinical motor impairment of the limbs +/- impairment of the
             bulbar muscles.

          -  Patients with a clinical motor impairment on the deltoid muscle (MRC score&lt;5)

        For control patients:

          -  Age between 45 and 70 years old

          -  Patients having an orthopedic surgery of the shoulder with a normal neurological
             examination

          -  Patients having a peripheral neuropathy with a motor component needing a biological
             blood sample, a lumbar puncture for CSF examination and a neuro-muscular biopsy for
             complete diagnostic

          -  Patients having a muscular myopathy needing a biological blood sample and a deltoid
             muscle biopsy for complete diagnostic.

          -  Patients affiliated to a governmental health plan

          -  Clear and loyal consent form written and signed by the patient and the investigator (
             before any exam and at least the day of inclusion)

        Exclusion Criteria:

          -  Patients not eligible for a muscle biopsy (anti-coagulation, anti aggregation or blood
             coagulation pathologies)

          -  Patients not eligible for lumbar puncture (anti-coagulation, anti aggregation or blood
             coagulation pathologies, recent spine surgery, acquired or congenital spine
             malformation, clinical signs of intracranial hypertension, cutaneous infection at the
             punction site).

          -  ALS patient with isolated bulbar symptoms

          -  Patients with a clinical syndrome of ALS-plus associating extra-pyramidal symptoms,
             cerebellar or spino-cerebellar syndromes autonomic disorders or ocular palsy.

          -  Patients with marked cognitive impairments (MMS&lt;24/30 or BREF&lt;14/18)

          -  Pregnant or breastfeeding women

          -  Patients with any neurological or non-neurological disorders interfering with the
             ALSFRS score

          -  Patients who could not express their consent

          -  Patients in emergency situation

          -  Patients under guardianship or judicial protection

          -  Pace maker, cochlear implant

          -  Spinal cord compression or trauma

          -  Spine surgery

          -  Spinal deformity

          -  Claustrophobia

          -  Metallic foreign body

          -  Pregnancy

          -  Vital capacity &lt; 50 %
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Cécile WIELANEK-BACHELET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodolphe THIEBAUT, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Cécile WIELANEK-BACHELET, MD</last_name>
    <email>anne-cecile.wielanek@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Cécile WIELANEK-BACHELET, MD</last_name>
      <email>anne-cecile.wielanek@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Cécile WIELANEK-BACHELET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gwendal LE MASSON, Md, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier FERRER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guilhem SOLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry FABRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>January 8, 2015</last_update_submitted>
  <last_update_submitted_qc>January 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>miRNA</keyword>
  <keyword>biomarker</keyword>
  <keyword>monocentric observational study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

